Navigation Links
Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
Date:2/19/2008

The Next Step Involves Combining the 350+ Targeted Drugs on the Market and in Clinical Development with Each Other to Block Key Pathways to Combat Drug Resistance, Enhance Anticancer Effects, and Expand the Markets for

Targeted Drugs

LAKE FOREST, Calif., Feb. 19 /PRNewswire/ -- Identification of novel cancer-related targets and pathways is redefining our understanding of the nature of malignancy. Molecular profiling is prompting new, more detailed classifications of malignancy enabling the development of specific/personalized cancer therapies. Standard classifications involving gross pathologic hallmarks such as stage and grade are now being further augmented by data detailing the overexpression of oncogenes, silencing of tumor suppressors and presence of mutant forms of relevant markers. In each of these cases novel targeted agents and various combination strategies are being investigated based on the specific molecular profiles of cancer subtypes.

Molecular Profiling Improves Classification and Guides Treatment

In breast cancer, for example, classification has been extended to include metastatic sites (bone, brain), expression of HEr2, and hormone receptor status. A recently introduced classification is triple negative (Er-, Pgr- and HEr2-) breast cancer, also known as basal-cell cancer. Other classifications include inflammatory breast cancer and ductal carcinoma in situ. Different treatment strategies are in development for each of these tumor types. Similarly, most other malignancies are also undergoing reclassification based on specific molecular profiles. Elucidation of the role of Kras in the success or failure of EGFr inhibition in the treatment of colorectal cancer exemplifies the recent remarkable achievements that have been made based on molecular profiling. Authoritative cancer agencies are taking notice. The National Comprehensive Cancer Network (NCCN) has begun to incorporate diagnostic, prognostic and pharmacogenomic evaluations in their updated treatment guidelines.

Targeted Agents in Combination are Entering Clinical Trials

The validated association of aggressive disease and the overexpression of HEr2 in any type or stage of breast cancer have created a $4 billion global market for trastuzumab (Herceptin; Genentech) in 2007. Still, nearly 50% of HEr2-positive patients do not respond to trastuzumab, and survival benefits are transient, often lasting under a year. Furthermore, side effects remain a significant problem. Despite these limitations, trastuzumab is the standard of treatment for both early stage and advanced or metastatic disease and is undergoing clinical trials in combination with numerous approved or novel anticancer agents.

Hundreds of clinical trials are underway combining approved targeted therapeutics with every applicable cytotoxic(s) with the goal of achieving incremental benefits. The greater opportunity, however, may lie in combining targeted therapeutics that address different points in one pathway or interacting pathways involved in angiogenesis, metastasis, drug resistance, and tumor growth and survival. This approach has entered the clinic; recently initiated trials are testing combinations of approved targeted therapeutics with each other. The full impact of combining target agents, however, will not be measured until approved and novel agents are combined in hundreds of different combinations for the treatment of hundreds of specific cancer indications.

Future Oncology Series Details ErbB Pathway-targeted Therapeutics

To date, ErbB pathway abnormalities, which occur in a large number of malignancies, have been the most extensively targeted. Currently, there are 7 approved agents targeting this pathway and over 620 clinical trials are ongoing with these agents in various combinations, mostly with cytotoxic agents but also with each other and with selected novel agents under clinical development. In addition to the over 56 ErbB-targeted agents in development (35 in current clinical trials), numerous molecular markers/pathways are being recognized as contributing to the success or failure of the ErbB pathway inhibitors. A series of reports (http://www.newmedinc.com/futonc/sample.pdf) on currently approved therapeutics as well as those in development targeting the ErbB pathway, including EGFr and HEr2 inhibitors, published by Future Oncology (http://www.newmedinc.com), highlights the contribution of molecular profiling in the characterization of cancer and its treatment.

New Medicine's Oncology KnowledgeBASE (nm|OK) is a Complete Knowledge Environment in Drug Development in Cancer

Unlike standard drug databases, nm|OK residing at http://www.nmok.net, is designed to specifically provide a fully realized environment reflecting every aspect of drug development in oncology. nm|OK is an edited, inclusive analysis of all aspects of oncology drug development worldwide, including technologies, targets, companies, business affiliations, medical and clinical developments, protocols and results of thousands of clinical trials, and global markets, among others. Currently, nm|OK profiles over 2,000 anticancer agents/technologies in current development (over 4,000 drugs overall) or on the market, more than 1,200 targets implicated in malignancy, and more than 2,000 companies developing/marketing products in the oncology sector. Protocols, interim and final results are presented for thousands of trials, searchable by both novel and approved agents in monotherapy or combination therapy regiments. In addition, nm|OK describes hundreds of diagnostic, prognostic, and theragnostic methodologies and products as they relate to treatment candidate selection, evaluation of the results of clinical trials, and early and accurate detection of disease.

Contact us for an online demonstration of nm|OK.

Contact: Katie Siafaca

New Medicine, Inc.

Tel: (949) 830-0448; Fax: (949) 830-0887

E-mail: info@newmedinc.com

http://www.newmedinc.com/

http://nmok.net/

http://nmok.net/oksite/samprecords.html


'/>"/>
SOURCE New Medicine, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
2. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
3. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
4. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
5. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
9. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
10. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017  Noble Capital Markets announced today that ... (Nasdaq: EPIX ). The report was issued ... , PhD. ESSA Pharmaceuticals is a clinical ... cancer (CRPC). Its lead compound EPI-506, is a small ... of the androgen receptor, thereby has potential to overcome ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... company, today announced that executive management will participate in ... held February 22-23, 2017. Adrian Adams , Chief ... at 1:35 p.m. local time on Wednesday, February 22, ... for the event may be accessed from the Investors ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... For ... assistance management solution to the exhibit floor for the 2017 HIMSS Conference ... , From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from ... February 21 - 23 in Beaver Creek, CO. It was announced today by Cindy ... year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs of ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
Breaking Medicine News(10 mins):